Cara Marie Rogers

Dr. Cara Marie Rogers


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Molecular Imaging
Verified
Journal Article
Open access
PDF file
BSBrittany M. Stopa
Brittany M. Stopa
JCJames Crowley
James Crowley
CJCsaba Juhasz
Csaba Juhasz
CRCara Marie Rogers
Cara Marie Rogers
MWMark R. Witcher
Mark R. Witcher
JKJackson William Kiser
Jackson William Kiser
Introduction. Positron emission tomography (PET) imaging with prostate-specific membrane antigen- (PSMA-) binding tracers has been found incidentally to demonstrate uptake in CNS tumors. Following the encouraging findings of several such case reports, there is a growing interest in the potential application of PSMA-targeted PET imaging for diagnostics, theranostics, and monitoring of CNS tumors. This is a systematic literature review on PSMA-binding tracers in CNS tumors. Methods. A PubMed search was conducted, including preclinical and clinical reports. One hundred and twelve records were identified, and after screening, 56 were included in the final report. Results. Tissue studies demonstrated PSMA expression in tumor vascular endothelial cells, without expression in normal brain tissue, though the extent and intensity of staining varied by anti-PSMA antibody and methodology. Most included studies reported on gliomas, which showed strong PSMA ligand uptake and more favorable tumor to background ratios than other PET tracers. There are also case reports demonstrating PSMA ligand uptake in prostate cancer brain metastases, nonprostate cancer brain metastases, and meningiomas. We also review the properties of the various PSMA-binding radiotracers available. Therapeutic and theranostic applications of PSMA-binding tracers have been studied, including labeled alpha- and beta-ray emitting isotopes, as well as PSMA targeting in directing MRI-guided focused ultrasound. Conclusions. There is a potential application for PSMA-targeted PET in neuro-oncology as a combination of diagnostic and therapeutic use, as a theranostic modality for managing CNS tumors. Further research is needed regarding the mechanism(s) of PSMA expression in CNS tumors and its differential performance by tumor type.

31 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAbhishek Bhutada
Abhishek Bhutada
SASrijan Adhikari
Srijan Adhikari
JCJoshua Aaron Cuoco
Joshua Aaron Cuoco
AIAlexander In
Alexander In
CRCara Marie Rogers
Cara Marie Rogers
EMEric A. Marvin
Eric A. Marvin
Background: Choroid plexus tumors (CPTs) are rare neoplasms found in the central nervous system, comprising 1% of all brain tumors. These tumors include choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Although gross total resection for choroid plexus papillomas (CPPs) is associated with long-term survival, there is a scarcity of prospective data concerning the role and sequence of neoadjuvant therapy in treating aCPP and CPC. Methods: From the years 2000 to 2019, 679 patients with CPT were identified from the Surveillance, Epidemiology, and End Result (SEER) database. Among these patients, 456 patients had CPP, 75 patients had aCPP, and 142 patients had CPC. Univariate and multivariable Cox proportional hazard models were run to identify variables that had a significant impact on the primary endpoint of overall survival (OS). A predictive nomogram was built for patients with CPC to predict 5-year and 10-year survival probability. Results: Histology was a significant predictor of OS, with 5-year OS rates of 90, 79, and 61% for CPP, aCPP, and CPC, respectively. Older age and African American race were prognostic for worse OS for patients with CPP. Older age was also associated with reduced OS for patients with aCPP. American Indian/Alaskan Native race was linked to poorer OS for patients with CPC. Overall, treatment with gross total resection or subtotal resection had no difference in OS in patients with CPP or aCPP. Meanwhile, in patients with CPC, gross total resection (GTR) was associated with significantly better OS than subtotal resection (STR) only. However, there is no difference in OS between patients that receive GTR and patients that receive STR with adjuvant therapy. The nomogram for CPC considers types of treatments received. It demonstrates acceptable accuracy in estimating survival probability at 5-year and 10-year intervals, with a C-index of 0.608 (95% CI of 0.446 to 0.77). Conclusions: This is the largest study on CPT to date and highlights the optimal treatment strategies for these rare tumors. Overall, there is no difference in OS with GTR vs. STR in CPP or aCPP. Furthermore, OS is equivalent for CPC with GTR and STR plus adjuvant therapy.

10 November 2018 in Cureus
Verified
Journal Article
Open access
PDF file
CRCara Marie Rogers
Cara Marie Rogers
CBChristopher M. Busch
Christopher M. Busch
JCJoshua Aaron Cuoco
Joshua Aaron Cuoco
ZEZev Elias
Zev Elias
GSGary R. Simonds
Gary R. Simonds
The unsustainable cost of healthcare in the United States has made it important for all healthcare professionals to examine their practices for wasteful spending and work to mitigate these costs. When neurosurgical patients remain hospitalized beyond the point of maximum inpatient benefit, this represents a potential source of healthcare economic waste. The objective of this study was to determine the direct and indirect costs to a hospital system when neurosurgical patients remain hospitalized past the maximum inpatient benefit and identify targets to improve this potential wasteful spending. We performed an extensive chart review of all patients admitted to our neurosurgical service from the months of July to October 2016, who had been deemed medically stable for discharge but remained in the hospital past their ideal date of discharge. We analyzed for significant trends in patient factors, procedural acuity, disposition, funding, and other factors that contributed to the delays in discharge. A total of 334 patients were admitted to the Carilion Clinic-Virginia Tech Carilion (CC-VTC) inpatient neurosurgery service, and 50 of these admissions (15%) resulted in medically unnecessary prolonged hospitalizations. These patients were hospitalized for a total of 324 days past the dates of ideal discharge. Elective cases had the maximum number of prolonged hospitalizations, while the emergent cases had the maximum number of prolonged hospitalization days. Patients with private insurance had the shortest number of prolonged hospitalization days, and uninsured patients had the longest. Patients requiring disposition to a rehabilitation or a nursing facility remained in the inpatient setting for longer periods than those destined for home. The most common factors limiting appropriate discharge were related to bed availability at outside facilities, funding issues, and differing opinions on appropriate disposition. The medically unnecessary days accounted for 41% of the total hospitalization but accounted for only 12.9% of the billable charges. The billable cost per medically necessary day was $17,326 in comparison to a medically unnecessary day of $2,070. Indirect costs were inferred from these patients utilizing beds and resources that could have been allocated to others with acute needs, given that our hospital is at capacity and on diversion, a significant percentage of the time. Neurosurgical patients remaining hospitalized past their maximal inpatient benefit have a significant economic impact on a hospital system. Identifying patients who are at risk for prolonged hospitalizations may provide us with the targets for improvement to mitigate this healthcare economic waste.

9 August 2018 in Cureus
Verified
Journal Article
Open access
PDF file
JCJoshua Aaron Cuoco
Joshua Aaron Cuoco
CBChristopher M. Busch
Christopher M. Busch
CRCara Marie Rogers
Cara Marie Rogers
EGEvin L. Guilliams
Evin L. Guilliams
BKBrendan J. Klein
Brendan J. Klein
EMEric A Marvin
Eric A Marvin
The Accreditation Council for Graduate Medical Education and the American Osteopathic Association recently agreed to establish a single graduate medical education system for the United States allopathic and osteopathic resident physicians by 2020. Consequential to this merger, new standards will be implemented for academic and research requirements within medical schools as well as residency programs. In the United States, osteopathic medicine is considered to be a parallel profession to allopathic medicine. However, recent studies have revealed that the percentages of United States osteopathic physicians currently in practice are not proportional to the percentages of editorial board member positions they hold in several high-profile medical journals as well as neurosurgical journals. To our knowledge, there is currently no published literature examining osteopathic physician author representation of any neurosurgical journal. In the present study, we analyze the number of osteopathic physicians and osteopathic neurosurgeons serving as authors in prominent neurosurgical journals. American neurosurgical journals with the highest number of citations plus an affiliation with a neurosurgical society open to osteopathic neurosurgeons were used as criteria for journal selection. The Journal of Neurosurgery Publishing Group journals (Journal of Neurosurgery, Journal of Neurosurgery: Spine, Journal of Neurosurgery: Pediatrics, and Neurosurgical Focus) fulfilled these criteria. The number of allopathic and osteopathic physicians who have published at least one manuscript in a Journal of Neurosurgery Publishing Group journal was counted. The specialty of each osteopathic author was examined. Our analysis found that allopathic physicians represented 105,157 (99.68%) and osteopathic physicians represented 335 (0.32%) of the 105,492 authorship positions held by these physicians in these journals since 1944. Statistical significance was found comparing the number of allopathic authors versus the number of osteopathic authors (p < 0.0001). The most common specialty represented by osteopathic authors in all journals was neurosurgery (45%). Osteopathic neurosurgeons represented 153 (0.15%) of the total number of allopathic and osteopathic authors. These data establish that the percentages of the United States osteopathic physicians and osteopathic neurosurgeons currently in practice are not proportional to the percentages of authorship positions they hold in Journal of Neurosurgery Publishing Group journals. We postulate that this apparent disproportionality may originate from significant differences between allopathic and osteopathic medical school research funding, research opportunities, scholarly activities, and dual-degree programs.

20 April 2022 in World Neurosurgery
Verified
Journal Article
Closed access
BSBrittany M. Stopa
Brittany M. Stopa
JCJoshua A. Cuoco
Joshua A. Cuoco
MSMichael S. Stump
Michael S. Stump
CRCara Marie Rogers
Cara Marie Rogers

30 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Liliana LadnerLiliana Ladner
Liliana Ladner
SASrijan Adhikari
Srijan Adhikari
ABAbhishek S. Bhutada
Abhishek S. Bhutada
JCJoshua Aaron Cuoco
Joshua Aaron Cuoco
VPVaibhav M. Patel
Vaibhav M. Patel
EMEric A. Marvin
Eric A. Marvin
Brain metastases are an uncommon yet life-limiting manifestation of prostate cancer. However, there is limited insight into the natural progression, therapeutics, and patient outcomes for prostate cancer once metastasized to the brain. This is a retrospective study of 461 patients with metastatic prostate cancer to the brain with a primary outcome of median overall survival (OS). The Surveillance, Epidemiology, and End Results (SEER) database was examined using Cox regression univariate and multivariable analyses, and a corresponding nomogram was developed. The median overall survival was 15 months. In the multivariable analysis, Hispanic patients had significantly increased OS (median OS 17 months, p = 0.005). Patients with tumor sizes greater than three centimeters exhibited significantly reduced OS (median OS 19 months, p = 0.014). Patients with additional metastases to the liver exhibited significantly reduced OS (median OS 3.5 months, p < 0.001). Increased survival was demonstrated in patients treated with chemotherapy or systemic treatment (median OS 19 months, p = 0.039), in addition to radiation and chemotherapy (median OS 25 months, p = 0.002). The nomogram had a C-index of 0.641. For patients with prostate metastases to the brain, median OS is influenced by race, tumor size, presence of additional metastases, and treatment. The lack of an association between traditional prostate cancer prognosis metrics, including Gleason and ISUP grading, and mortality highlights the need for individualized, metastasis-specific prognosis metrics. This prognostic nomogram for prostate metastases to the brain can be used to guide the management of affected patients.